Brief: EMAValidates Nanexa's Clinical Trial Application For Of NEX-22
Dec 20 (Reuters) - Nanexa AB NANEXA.ST :
* NANEXA’S CLINICAL TRIAL APPLICATION FOR NEX-22 PHASE I
STUDY
ASSESSED BY EMA
* CLINICAL TRIAL APPLICATION FOR PHASE I STUDY OF NEX-22 IN
PATIENTS WITH TYPE 2 DIABETES HAS BEEN RECEIVED AND VALIDATED BY
EUROPEAN MEDICINES AGENCY (EMA)
Source text for Eikon: ID:nMFN5mnYy6
Further company coverage: NANEXA.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Nanexa AB
See all newsNanexa shares soar on €1.17 billion Novo Nordisk deal for injection technology
Brief: Nanexa And Novo Enter Global License, Collaboration Deal
Brief: Forge Nano And Nanexa To Develop Gmp-Compatible Ald Manufacturing Equipment
Brief: Nanexa Q2 Revenue Amounted To SEK 1.7 Million
Sweden's Nanexa Q1 revenue falls, loss widens